Search Results
Sort by:
Filter 0
Sort by
17 September 2024 - EA65
Pharmacokinetics/Pharmacodynamics (PK/PD) of a Novel Nystatin-like Drug, BSG005, in Invasive Pulmonary Aspergillosis (IPA) and Invasive Candidiasis (IC)
29 April 2024 - P2751
Higher Blastomyces dermatitidis initial antigen levels associated with disseminated disease, use of amphotericin B, and mortality
28 April 2024 - P2273
Identification of candidate in vitro susceptibility test interpretive criteria (STIC) for oral cephalosporin antimicrobial agents against Escherichia coli and Staphylococcus aureus
18 April 2023 - O1143
SF001: a third-generation broad-spectrum, renal sparing polyene antifungal
17 April 2023 - P2197
In vivo PK/PD characterization of a novel polyene SF001 in the invasive pulmonary aspergillosis (IPA) mouse model
04 October 2022 - EA69
Real-World Analysis of New Antibiotic Use at a US Medical Center with Multi-Drug Resistant (MDR) Pseudomonas aeruginosa (PSA) but a Paucity of Carbapenemase-Producing Enterobacterales (CPE)
04 October 2022 - EA61
In vivo Pharmacodynamic Evaluation of Meropenem-Nacubactam in Murine Thigh and Lung Infection Models against Klebsiella pneumoniae (KPN) containing OXA-48-like Enzymes
04 October 2022 - EA62
In vivo Pharmacodynamic Evaluation of CRS0540 in the Murine Thigh and Lung Infection Models against Staphylococcus aureus
24 April 2022 - O0301
Development of modernised Acinetobacter baumannii susceptibility guidance for recommended antimicrobial agents using pharmacometric approaches
23 April 2022 - O0115
In vivo pharmacodynamic evaluation of meropenem-nacubactam in murine thigh and lung infection models against Klebsiella pneumoniae (KPN) containing OXA-48-like enzymes
16 April 2019 - O1066
In vivo pharmacodynamic evaluation of the novel antifungal agent APX001 in a murine model of invasive pulmonary aspergillosis against wild-type and Cyp51 mutant Aspergillus fumigatus strains
15 April 2019 - P2129
Cefepime time above MIC PK/PD target determination when combined with the novel beta-lactam enhancer zidebactam in a murine pneumonia model against carbapenemase-producing Enterobacteriaceae including those with metallo-beta-lactamase enzymes
15 April 2019 - P1984
Achievement of clinical isavuconazole serum and plasma trough concentrations in seven patients with isavuconazonium capsules administered via an enteral feeding tube
24 April 2018 - O0944
Pharmacodynamic (PD) evaluation of rezafungin (CD101) against Candida auris in the persistently neutropenic murine model of disseminated candidiasis
23 April 2018 - O0797
Pharmacokinetics/pharmacodynamics (PK/PD) of the novel, first-in-class glycosylphosphatidylinositol (GPI) Inhibitor APX001 in the neutropenic murine invasive candidiasis model against C. albicans (CA), C. glabrata (CG), and C. auris (CAU)
23 April 2018 - O0794
Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis
22 April 2018 - O0422
Meropenem-vaborbactam versus best available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: outcomes in all treated patients regardless of pathogen
25 April 2017 - EP0948
Comparative pharmacokinetics/pharmacodynamics (PK/PD) of telavancin and vancomycin in the murine thigh and lung infection models against Staphylococcus aureus (SA)
Loading ...
+ load more
FAQ
To access content in the Library you need to log in with your ESCMID member or user credentials. If you haven’t registered as an ESCMID member yet, then click here to do so – or use this link to register as a user.
The most recent event-related content is usually restricted to ESCMID members, while registered users get access one year after the event. However, there are events such as ESCMID Global where attendees get priority access, no matter if they are members or registered users. In these cases, we may offer non-attendees access after paying a fee.
You may search by event name, session title or number, topic title or number or author – or by any keyword. To get the most relevant results, enter the title or name in quotation marks, e.g. "Pre-ECCMID Day on Diagnostics" or "John Doe". If no quotation marks are used, then the exact result is shown first, followed by less exact results.
You may further narrow the number of search results for most terms by applying one or several filters, using the filter window on the start page. The Category and Media Type filters work for any content. In contrast, the Date from / to filter may not apply for Publications and Guidelines. In addition, the information text below a webcast or document offers the option of filtering search results by session title, author, event or category.
We defined four "hot topic" terms that you may search for by clicking the four tiles on the start page.
Linking two or more search terms by AND will show all results containing these search terms. For example, if you are looking for results that contain both the terms viral and hospital, then enter viral AND hospital.
Link two or more search terms by OR to get all results that contain at least one of these terms. For example, if you want to get results that contain either viral or infections or COVID, then enter viral OR infections OR COVID.
Place + in front of the term that you want to be included in your search result and place - in front of the term that you do not want to be included – without blanks in between in either case. For example, if you are aiming for search results that contain viral and infection but do not contain COVID, then enter +viral +infections -COVID.
A search term preceded by an exclamation point (no blanks in between) will lead to all content that does not contain the term, e.g. !COVID.
Deselect the ticked boxes in the filter dropdowns, click "Clear" on the calendars in the Date from / to filter – or refresh the website to remove all filters at once. Additionally, you may clear all applied filters by using the relevant buttons right above the search results.
No, as copyright protection limits the viewing of video presentations to web browsers, they cannot be downloaded.
No, due to our privacy policy we cannot disclose any contact details of persons involved.